Merz Pharma withdrew its offer for Obagi Medical, clearing the path for its own $420 million merger with Valeant Pharmaceuticals International Inc.
Valeant continues to expand through aggressive acquisitions of prescription and generic drug makers.
Obagi Medical Products (Nasdaq:OMPI) has been downgraded by TheStreet Ratings from from a buy to hold.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.